BioTuesdays

Tag - SLRX

Salarius Pharmaceuticals

Ladenburg starts Salarius Pharma at buy; PT $3.80

Ladenburg Thalmann launched coverage of Salarius Pharmaceuticals (NASDAQ:SLRX) with a “buy” rating and price target of $3.80. The stock closed at 63 cents on April 24. Salarius obtained a NASDAQ listing through a...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.